Search Results
Sep 08, 2026, 07:00 ET Hirain and Arbe Selected by One of the World's Largest Automotive Groups for Level 3 Program Across Multiple Brands
includes Automotive Electronics, R&D Services and Solutions, integrated systems and specialized vehicles, and intelligent transportation solutions to clients worldwide.Headquartered in Beijing, Hirain has built an integrated ecosystem encompassing marketing, R&D, manufacturing, operations, and
More news about: Arbe
Sep 08, 2026, 06:53 ET Spirox lance un système d'inspection des fissures à grande vitesse pour TGV destiné à faciliter l'inspection de grands volumes de substrats en verre
essentielles à la production. Conçu pour répondre aux besoins de la production en grande série, le SP7000G, associé au SP8000G de Spirox, destiné à la R&D et à l'analyse du contrôle qualité, permet d'offrir aux clients des capacités d'inspection et d'analyse sur l'ensemble du substrat plus rapides, plus
More news about: Spirox Corporation
Sep 08, 2026, 06:36 ET Spirox Launches High-Speed TGV Crack Inspection System to Support High-Volume Glass Substrate Inspection
SP7000G complements Spirox's SP8000G, providing a comprehensive solution for high-speed, precise, and non-destructive TGV inspection and analysis across R&D, quality control, and high-volume manufacturing. Spirox will continue to strengthen its proprietary inspection technologies and support customers in
More news about: Spirox Corporation
Sep 08, 2026, 06:19 ET IC Optimize Announces Odin and Joins the Cadence Connections Program
https://news.cision.com/ic-optimize/r/ic-optimize-announces-odin-and-joins-the-cadence-connections-program,c4393228The following files are available for download:
More news about: IC Optimize
Sep 08, 2026, 06:16 ET IC Optimize Announces Odin and Joins the Cadence Connections Program
https://news.cision.com/ic-optimize/r/ic-optimize-announces-odin-and-joins-the-cadence-connections-program,c4393228The following files are available for download:
More news about: IC Optimize
Sep 08, 2026, 06:10 ET 歌禮宣布在美國啟動口服胰澱素受體激動劑多肽ASC36治療肥胖症的I期研究
復方制劑；ASC39，一款與eloralintide類似、強效的每日一次口服小分子胰澱素選擇性受體激動劑（SARA）；ASC30_39FDC，一款每日一次口服小分子雙靶點激動劑，為ASC30（GLP-1R激動劑）與ASC39（胰澱素選擇性受體激動劑（SARA））的固定劑量復方制劑；ASC36，一款胰澱素多肽，設計為每月一次至每季度一次皮下注射以及每日一次口服；ASC35，一款每月一次皮下注射GLP-1R/GIPR雙靶點激動劑多肽；ASC36_35FDC，一款每月一次皮下注射三靶點多肽激動劑，為ASC36（胰澱素受體激動劑）與ASC35（GLP-1R/GIPR激動劑）的固定劑量復方制劑；ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，設計為每月一次皮下注射及每日一次口服；以及ASC36_37FDC，一款每月一次皮下注射四靶點激動劑多肽，為ASC36（胰澱素受體激動劑）與ASC37（GLP-1R/GIPR/GCGR激動劑）的固定劑量復方制劑，用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲了解更多信息，敬請登錄網站：
More news about: 歌禮製藥有限公司
Sep 08, 2026, 06:10 ET Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide agonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be administered
More news about: Ascletis Pharma Inc.
Sep 08, 2026, 06:01 ET 페프로민 바이오, 기존 CD19 CAR T세포 치료 실패 포함 재발성/불응성 B세포 림프종에서 깊고 지속적인 완전관해 입증한 제1상 임상시험 결과 랜싯에 게재 발표
T세포 치료 후 림프종이 재발한 환자에게 새로운 표적은 새로운 기회를 의미할 수 있다. IFLI는 페프로민 바이오의 BAFF-R CAR T세포 치료제 개발을 지원하게 된 것을 자랑스럽게 생각하며, 이번에 나타난 초기의 지속적인 반응에 고무되어 있다"고 말했다.출판 정보제목: 재발성 또는 불응성 B세포 림프종에 대한 BAFF-R CAR T세포 치료(BAFF-R CAR T-cell therapy for relapsed or refractory B-cell lymphomas)학술지:
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio gibt die Veröffentlichung bahnbrechender Ergebnisse einer klinischen Phase-1-Studie in The Lancet bekannt, die tiefe und anhaltende vollständige Remissionen bei rezidivierten/refraktären B-Zell-Lymphomen belegen, auch nach vorherigem Versagen einer CD19-CAR-T-Zell-Therapie
BAFF-R-CAR-T-Zell-Therapie zu unterstützen, und sieht das frühe und anhaltende Ansprechen als ermutigend an", sagte Mehrdad Mobasher, M.D., M.P.H., geschäftsführender Partner beim Institute for Follicular Lymphoma Innovation.Angaben zur VeröffentlichungTitel: BAFF-R-CAR-T-Zell-Therapie
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure
PeproMene Bio in advancing BAFF-R CAR T-cell therapy and encouraged by these early, durable responses," said Mehrdad Mobasher, M.D., M.P.H., Executive Partner at the Institute for Follicular Lymphoma Innovation.Publication DetailsTitle: BAFF-R CAR T-cell therapy for relapsed
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure
PeproMene Bio in advancing BAFF-R CAR T-cell therapy and encouraged by these early, durable responses," said Mehrdad Mobasher, M.D., M.P.H., Executive Partner at the Institute for Follicular Lymphoma Innovation.Publication DetailsTitle: BAFF-R CAR T-cell therapy for relapsed
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio anuncia la publicación en The Lancet de los resultados de su ensayo clínico de fase 1
terapia con células T CAR BAFF-R y se siente alentado por estas respuestas tempranas y duraderas", declaró Mehrdad Mobasher, M.D., M.P.H., socio ejecutivo del Instituto para la Innovación en Linfoma Folicular.Detalles de la publicaciónTítulo: BAFF-R CAR T-cell therapy for relapsed
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio annonce la publication dans The Lancet des résultats d'un essai clinique de phase 1 démontrant des réponses complètes profondes et durables dans les lymphomes à cellules B récidivants ou réfractaires, y compris après l'échec d'un traitement par cellules CAR-T ciblant le CD19
thérapie par cellules CAR-T BAFF-R et se réjouit de ces premières réponses durables », déclare le Dr Mehrdad Mobasher, M.D., M.P.H., associé exécutif à l'Institute for Follicular Lymphoma Innovation.Informations sur la publicationTitre : BAFF-R CAR T-cell therapy for relapsed
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:00 ET Spirox Launches High-Speed TGV Crack Inspection System to Support High-Volume Glass Substrate Inspection
SP7000G complements Spirox's SP8000G, providing a comprehensive solution for high-speed, precise, and non-destructive TGV inspection and analysis across R&D, quality control, and high-volume manufacturing. Spirox will continue to strengthen its proprietary inspection technologies and support customers in
More news about: Spirox Corporation
Sep 08, 2026, 05:17 ET Raghav Productivity Enhancers Ltd and TRL Krosaki announce strategic JV to set up a 350,000 MTPA silica ramming mass plant in Odisha
network closer to key consumption centers.The JV brings together RPEL's patented manufacturing technology, established market presence and R&D capabilities with TRL Krosaki's regional strength, quartzite resources in Odisha and global refractory expertise, backed by Krosaki Harima Corporation,
More news about: Raghav Productivity Enhancers Ltd.
Sep 08, 2026, 05:00 ET IFA 2026 : Tineco dévoile une nouvelle génération d'innovations pour un nettoyage toujours plus intelligent et autonome
propos de TinecoTineco est une entreprise high-tech et une filiale détenue à 100 % par le groupe ECOVACS (SHA : 603486), dédiée à la R&D de technologies innovantes et à la conception de produits électroniques intelligents haut de gamme pour la maison. Fondée en 1998 avec son premier
More news about: Tineco
Sep 08, 2026, 04:48 ET ECOVACS Defines the Future of Robotic Floor Cleaning with Third-Generation OZMO ROLLER Technology
around the cleaning task as a whole.ECOVACS has been granted more than 3,100 patents and invested more than RMB 5.2 billion in R&D since 2018. These capabilities support the company's ability to translate insights from real-world use into successive generations of technology.
More news about: ECOVACS ROBOTICS
Sep 08, 2026, 04:38 ET ECOVACS Defines the Future of Robotic Floor Cleaning with Third-Generation OZMO ROLLER Technology
around the cleaning task as a whole.ECOVACS has been granted more than 3,100 patents and invested more than RMB 5.2 billion in R&D since 2018. These capabilities support the company's ability to translate insights from real-world use into successive generations of technology.
More news about: ECOVACS ROBOTICS
Sep 08, 2026, 04:30 ET Sungrow Perkenalkan MGTL Series, Inovasi Terbaru untuk Rumah dan Bisnis
dan Tangguh dengan Ekosistem Baterai TerbukaKeselamatan pengguna menjadi salah satu prioritas utama Sungrow. MGTL Series memiliki AFCI 3.0R sebagai fitur standar untuk mendeteksi gangguan busur listrik dengan jangkauan kabel hingga 200 meter dan arus deteksi 20A. Fitur ini turut meningkatkan
More news about: Sungrow
Sep 08, 2026, 04:21 ET SANY Heavy Industry H1 2026 Revenue Rises 19.49% YoY to USD 7.89 Billion, with Overseas Revenue Accounting for 61.33%
and operations closer to local markets.SANY will advance globalization, digitalization and decarbonization, reform overseas organization and R&D management, strengthen product innovation, and improve manufacturing, quality, profitability and competitiveness. It aims to deliver smarter, more
More news about: SANY Heavy Industry
Sep 08, 2026, 04:17 ET Epicyt Pharma reports positive results in first-in-human study of BAFA in patients following gastric bypass surgery
https://news.cision.com/epicyt-pharma-ab/r/epicyt-pharma-reports-positive-results-in-first-in-human-study-of-bafa-in-patients-following-gastric,c4392654The following files are available for download:
More news about: Epicyt Pharma AB
Sep 08, 2026, 04:06 ET Autoliv Advances Vehicle Safety Through Virtual Testing
https://news.cision.com/autoliv/r/autoliv-advances-vehicle-safety-through-virtual-testing,c4392743The following files are available for download:
More news about: Autoliv
Sep 08, 2026, 04:05 ET /C O R R E C T I O N -- GCCL/
commitment to supporting global drug development.At its exhibition booth, GCCL showcased its integrated Central Lab, Bioanalytical Lab and R&D Lab capabilities, which support clinical development from early- through late-stage trials. The company also held partnering discussions with pharmaceutical
More news about: GCCL